What is the recommended starting dose of Rexulti (brexpiprazole) for treating depression and post‑traumatic stress disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Rexulti Starting Dose for Depression and PTSD

For depression, start Rexulti at 0.5 mg or 1 mg once daily; for PTSD, start at 2 mg brexpiprazole combined with sertraline 150 mg daily.

Depression (Major Depressive Disorder)

The FDA-approved starting dose for adjunctive treatment of MDD is 0.5 mg or 1 mg orally once daily 1. The dosing algorithm proceeds as follows:

  • Days 1-7: Start at 0.5 mg or 1 mg once daily
  • Week 2: Titrate to 1 mg once daily if started at 0.5 mg
  • Week 3+: Increase to target dose of 2 mg once daily based on clinical response and tolerability
  • Maximum dose: 3 mg once daily

Titration should occur at weekly intervals, allowing adequate time to assess response and tolerability 1. The target therapeutic dose is 2 mg daily, which demonstrated optimal efficacy in clinical trials 2, 3. A meta-analysis specifically examining dose-response relationships found that 1-2 mg achieves the optimal balance between efficacy and tolerability, with efficacy peaking around 2 mg and then plateauing or slightly declining at 3 mg 3.

Important Caveats for Depression Dosing

  • CYP2D6 considerations: If the patient is a known CYP2D6 poor metabolizer, administer half the recommended dosage 1. However, in clinical MDD trials, doses were not adjusted for strong CYP2D6 inhibitors (like paroxetine or fluoxetine), so this is already factored into general dosing recommendations 1.

  • Renal impairment: Maximum dose is 2 mg daily if creatinine clearance <60 mL/minute 1

  • Hepatic impairment: Maximum dose is 2 mg daily for moderate to severe hepatic impairment (Child-Pugh score ≥7) 1

PTSD (Post-Traumatic Stress Disorder)

For PTSD, the evidence supports a different approach. Brexpiprazole is not FDA-approved as monotherapy for PTSD. The recent Phase 3 trial that demonstrated efficacy used brexpiprazole 2-3 mg daily in combination with sertraline 150 mg daily 4.

PTSD Dosing Protocol (Based on Clinical Trial)

The combination treatment protocol was:

  • Brexpiprazole: 2-3 mg daily (flexible dosing)
  • Sertraline: 150 mg daily (fixed dose)
  • Duration: 11 weeks in the trial

This combination demonstrated statistically significant improvement in PTSD symptoms (CAPS-5 total score) compared to sertraline plus placebo, with a least squares mean difference of -5.59 points (P<0.001) 4.

Critical Limitations for PTSD Use

A major caveat: The brexpiprazole-sertraline trials had highly restrictive inclusion/exclusion criteria. A real-world analysis found that approximately 95% of patients with PTSD seen in clinical practice would not have qualified for these trials 5. Specifically excluded were patients with:

  • Current major depressive disorder
  • PTSD onset before age 16
  • Duration of PTSD ≥10 years

These exclusions eliminate most patients seen in typical psychiatric practice 5. Therefore, the generalizability of the PTSD dosing recommendations to real-world patients is highly uncertain.

Alternative PTSD Pharmacotherapy

If considering antidepressant monotherapy for PTSD (without brexpiprazole), the 2023 VA/DoD PTSD guidelines recommend paroxetine, sertraline, or venlafaxine as first-line pharmacotherapy options 6. However, a recent meta-analysis found that antidepressants have only modest efficacy in PTSD, with an overall standardized mean difference of 0.25 (small to medium effect size) 7. Paroxetine showed better efficacy (SMD 0.43) compared to sertraline (SMD 0.12) 7.

Monitoring Requirements

Regardless of indication, assess patient status, therapeutic response, and adverse effects within 1-2 weeks of initiation 8. This is particularly important for monitoring:

  • Suicidal thoughts and behaviors (especially in the first 1-2 months)
  • Akathisia and restlessness (most common adverse effects)
  • Weight gain
  • Metabolic parameters

Modify treatment if inadequate response after 6-8 weeks 8.

Clinical Decision Algorithm

For MDD adjunctive treatment:

  1. Start 0.5-1 mg daily
  2. Titrate to 1 mg at week 2
  3. Increase to 2 mg at week 3 if tolerated
  4. Consider 3 mg only if inadequate response at 2 mg after adequate trial

For PTSD:

  1. Consider brexpiprazole only in combination with sertraline
  2. Start sertraline 150 mg daily
  3. Add brexpiprazole 2 mg daily (titrate per MDD protocol if needed)
  4. Adjust to 3 mg if inadequate response
  5. Recognize that efficacy in typical clinical populations is uncertain

References

Related Questions

Can I start brexpiprazole (Braylar) 1.5 mg while tapering lithium 600 mg daily?
What are the recommended dosing regimens for Rexulti (brexpiprazole) in adults with schizophrenia, adults with major depressive disorder, and in elderly or moderately hepatically impaired patients?
What are the recommended dosing guidelines for brexpiprazole for schizophrenia and adjunctive treatment of major depressive disorder, including dose adjustments for hepatic impairment, renal impairment, and elderly patients?
Can brexpiprazole (Rexulti) be co‑prescribed with escitalopram (Lexapro) in an adult patient without contraindications such as serotonin syndrome, cardiac arrhythmias, or severe hepatic impairment?
What are the drug interactions and monitoring considerations when combining sertraline, brexpiprazole (Rexulti), and dexmethylphenidate (Focalin)?
Can a pituitary adenoma cause total blindness?
Should I receive a tick-borne encephalitis (FSME) vaccine after a tick bite, and what vaccination schedule is appropriate based on my prior immunization status?
Can iodinated contrast media cause an allergic reaction that precipitates an asthma attack?
What are the risks and complications of not using a rescue inhaler (e.g., albuterol) when experiencing wheezing?
For a patient after percutaneous coronary intervention, should I use apixaban or rivaroxaban, and what are the recommended dosing and antiplatelet therapy regimens?
What is the risk of developing Barrett's esophagus in patients with bulimia nervosa who have frequent self‑induced vomiting?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.